Understanding PET Imaging for Triple Negative Breast Cancer: A Complete Guide for Patients

Table of Contents

• Key Points
• What is Triple Negative Breast Cancer?
• Why PET Imaging Matters in Breast Cancer
• How This Research Review Was Conducted
• Key Findings: What the Research Revealed
• PET for Initial Staging and Diagnosis
• PET and Molecular Biomarkers: Predicting Treatment Options
• Monitoring Response to Chemotherapy
• PET and Long-Term Prognosis
• New Frontiers: PSMA Tracers and Radiomics
• What This Means for Patients
• Study Limitations
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• A systematic review of 28 studies with 2,870 TNBC patients found [18F]FDG PET/CT essential for staging, response prediction, and prognosis.
• In a 2016 study of 232 early-stage TNBC patients, PET/CT upstaged 15% of patients by detecting hidden distant metastases.
• In a study of 50 patients, a drop in SUVmax after one cycle of neoadjuvant chemotherapy predicted pathological complete response.
• In a study of 145 patients, high FDG uptake correlated with PDL-1 expression, suggesting possible immunotherapy benefit.
• PSMA-targeted tracers and radiomics are emerging areas, but evidence is preliminary with limited studies.

What is Triple Negative Breast Cancer?

Breast cancer is one of the most common cancers worldwide, and its treatment has evolved dramatically in recent decades. Among the many subtypes, triple-negative breast cancer (TNBC) stands out as particularly challenging. It is called "triple negative" because the cancer cells do not have three specific receptors—estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2)—that are commonly found on other breast cancer cells. Because these receptors are absent, hormonal therapies and HER2-targeted drugs like trastuzumab (Herceptin) do not work for TNBC.

TNBC accounts for approximately 15–20% of all breast cancer cases. It predominantly affects younger patients, typically those under 40 years old, and is associated with a higher rate of recurrence and a poorer prognosis compared to other breast cancer subtypes. For patients whose TNBC has spread to distant organs (metastatic disease), the median survival is only 1 to 1.5 years after diagnosis. This sobering statistic underscores the urgent need for better detection, staging, and treatment monitoring tools.

The lack of effective targeted therapies has historically limited treatment options for TNBC patients. However, the treatment landscape is rapidly evolving thanks to advances in molecular biology, immunotherapy, and precision medicine. New drugs are emerging, including:

• PARP inhibitors such as Olaparib and Talazoparib, which have been shown in clinical trials (OlympiAD and EMBRACA) to improve progression-free survival and objective response rates in advanced or metastatic TNBC patients with BRCA gene mutations
• Immune checkpoint inhibitors like Pembrolizumab, which demonstrated improved overall survival in TNBC patients with PD-L1-positive tumors in the KEYNOTE-522 trial
• Tyrosine kinase inhibitors, which target specific enzymes involved in cancer cell growth

Despite these advances, several challenges persist. Identifying new targets, exploring combination therapies, and developing reliable predictive biomarkers are crucial for improving treatment outcomes.

Why PET Imaging Matters in Breast Cancer

Positron emission tomography (PET) is an advanced imaging technique that shows how tissues in the body are functioning at the cellular level. Unlike CT (computed tomography) or MRI scans, which primarily show anatomy and structure, PET reveals metabolic activity—how actively cells are using energy. Cancer cells are typically highly metabolically active, so they "light up" on PET scans.

Breast cancer frequently overexpresses glucose transporters called GLUT 1–3, which makes it amenable to imaging with [18F]FDG PET/CT. [18F]FDG is a radioactive form of glucose that accumulates in cells that are using lots of energy—including fast-growing cancer cells. However, different breast cancer subtypes exhibit different levels of [18F]FDG avidity (how strongly they take up the tracer), reflecting differences in their glucose metabolism.

Critically, the scientific evidence shows that TNBC and HER2-enriched breast cancers typically show high [18F]FDG uptake, whereas luminal breast cancers—particularly the luminal A subtype—exhibit only faint uptake. This makes PET imaging potentially very useful specifically for TNBC patients.

The most recent ESMO (European Society for Medical Oncology) guidelines currently recommend [18F]FDG PET/CT only for specific clinical indications, such as when conventional imaging produces inconclusive results. However, these guidelines were based on a heterogeneous group of studies that often mixed different breast cancer subtypes and treatment regimens. This review was designed to specifically examine the evidence for PET imaging in TNBC patients alone.

How This Research Review Was Conducted

The researchers performed a systematic review, a rigorous method of research that gathers and analyzes all available scientific evidence on a specific question. They searched three major medical databases—PubMed, Scopus, and Web of Science—up to February 29, 2024, using search terms including "triple negative breast cancer" or "TNBC" combined with "PET/CT" or "positron emission tomography/magnetic resonance imaging."

A team of five researchers conducted the review with a clear division of responsibilities. Three reviewers (L.U., P.G., C.F.) conducted the literature search, while two other reviewers (L.F., L.E.) independently selected the studies to include, excluding duplicate papers. Any disagreements were resolved through consensus. The reference lists of selected papers were also carefully checked to identify any other potentially eligible studies that might have been missed in the initial search.

Only studies that met strict criteria were included:

• Original research articles (not reviews, editorials, meeting abstracts, or clinical reports)
• Studies involving human patients with TNBC (preclinical studies were excluded)
• Studies using modern hybrid PET/CT or PET/MRI scanners
• Papers published in English

Studies that mixed TNBC patients with other breast cancer subtypes were not considered. Additionally, if the same research group produced multiple papers that reused the same patient cohort or primarily confirmed previously published results, those papers were considered ineligible.

The quality of each selected study was assessed using a modified version of the Critical Appraisal Skills Programme (CASP) checklist, a standardized tool used to evaluate research quality. This assessment system uses 10 questions focused on the appropriateness of the research design, the clarity of the study aims, data collection methods, ethical considerations, and the rigor of the findings.

Because the studies were heterogeneous—varying in their clinical settings, patient populations, and methodologies—a meta-analysis (a statistical technique that combines results from multiple studies) was not performed. This was a deliberate choice to avoid drawing inappropriate conclusions from studies that weren't directly comparable.

Key Findings: What the Research Revealed

From the systematic literature search, twenty-eight papers were selected, including a total of 2,870 TNBC patients. This is a substantial body of evidence and represents one of the most comprehensive reviews of PET imaging in TNBC specifically.

Among the 28 selected studies, the majority (20 studies, or 71.4%) were retrospective, meaning they looked back at data from patients who had already been treated. Only 8 studies (28.6%) were prospective, meaning patients were enrolled and followed forward in time. While prospective studies generally provide stronger evidence, the inclusion of both types gives a fuller picture of the available data.

Quality assessment using the CASP tool showed variable quality across the studies:

• The aims of the research were clear in all selected studies
• The methodology was appropriate in 8 out of 27 papers (30%)
• The study design was unclear in 9 cases (33%)
• Ethical statements were released in 18 reports (67%)
• Overall value was rated low in 3 studies (11%), moderate in 6 (22%), and high in 16 (59%)

Most studies used [18F]FDG-based PET imaging. Notably, only two studies utilized PSMA-ligand agents, which is a newer area of investigation discussed later in this article.

The studies were organized into five main clinical areas based on how PET imaging was being used:

1. Correlation between [18F]FDG uptake and biomarker expression (AR, Ki67, PDL-1) — 1,034 patients (36.0%)
2. Neoadjuvant chemotherapy (NAC) setting — 715 patients (24.9%), covering response prediction, response monitoring, and prognostic stratification
3. Baseline staging and prognosis — 707 patients (24.6%)
4. PSMA-PET — 52 patients (1.8%)
5. Other applications (including [18F]FDG vs. MRI, heterogeneity, metastatic staging, and radiomic studies) — 362 patients (12.6%)

Interestingly, the ways in which researchers analyzed their data varied considerably. Nine papers (32.25%) used descriptive analysis, summarizing the observed patterns in their patient populations. Sixteen manuscripts (57.25%) used statistical analysis approaches such as Kaplan-Meier survival curves and univariate/multivariate analysis to determine the prognostic impact of PET in different contexts. One manuscript (3.5%) used a mixed approach, and two papers (7%) focused on describing the diagnostic performance of PET imaging.

PET for Initial Staging and Diagnosis

One of the most important roles of PET imaging in TNBC is baseline staging—determining exactly how far the cancer has spread at the time of diagnosis. This information is crucial because treatment decisions vary dramatically depending on whether the cancer is localized (confined to the breast and nearby lymph nodes) or has spread to distant organs.

The most dramatic evidence for the value of PET staging comes from a study by Ulaner and colleagues (2016), which followed 232 patients with early-stage TNBC (stage IIB or below). The researchers found that PET/CT upstaged 15% of patients with initial stage IIB TNBC, meaning it discovered unsuspected distant metastases (cancer spread) that had not been detected by conventional imaging. This is a substantial percentage—approximately 1 in 7 patients—and it directly influenced treatment decisions and survival outcomes. Patients who were upstaged to stage IV had their treatment plans completely redirected from curative intent (e.g., surgery and chemotherapy) to systemic management of metastatic disease.

In another study, Yue and colleagues (2015) examined 200 patients and found that [18F]FDG PET could further stratify TNBC into basal-like and non-basal-like subtypes based on their metabolic activity, potentially providing additional prognostic information beyond standard pathological testing.

These findings demonstrate that baseline [18F]FDG PET/CT provides information that goes beyond what conventional imaging offers. In TNBC, where the risk of early metastasis is high, this ability to catch hidden spread could be life-changing. The high [18F]FDG avidity of TNBC—meaning these tumors reliably show up brightly on PET scans—makes PET particularly well-suited for this purpose compared to other breast cancer subtypes.

PET and Molecular Biomarkers: Predicting Treatment Options

One of the most exciting areas of research involves the relationship between PET scan results and molecular biomarkers—measurable biological indicators that can predict how a patient's cancer will behave and which treatments are likely to work. This review identified four studies specifically exploring the correlation between [18F]FDG uptake and TNBC-correlated biomarkers, including androgen receptor (AR), programmed death protein ligand-1 (PDL-1), and Ki67.

Ki67: The Proliferation Marker

Ki67 is a protein that indicates how quickly cancer cells are dividing and multiplying. Higher Ki67 levels generally mean a more aggressive, fast-growing tumor. Two studies found significant correlations between [18F]FDG uptake and Ki67:

• Koo et al. (2015) — 103 patients: [18F]FDG uptake correlated with Ki67 and tumor size
• Tchou et al. (2009) — 22 patients: [18F]FDG uptake correlated with Ki67

For patients, this means a PET scan can serve as a non-invasive proxy for tumor aggressiveness. A brighter signal on PET may indicate a more rapidly dividing tumor, helping doctors gauge how aggressive the cancer is without relying solely on biopsy results.

Androgen Receptor: A Potential New Treatment Target

Two studies—Lee R. et al. (2022) with 608 patients and Lee H. et al. (2020) with 156 patients—demonstrated that lower [18F]FDG uptake predicted AR expression. AR-positive TNBC showed lower [18F]FDG uptake than AR-negative TNBC.

This finding is clinically significant because AR is being investigated as a potential therapeutic target in TNBC. If PET imaging can non-invasively indicate whether a tumor is likely AR-positive, it could help identify candidates for anti-androgen treatments—currently an area of active research—without requiring repeated biopsies.

PDL-1: The Immunotherapy Predictor

Choi and colleagues (2018) studied 145 patients and found a correlation between high [18F]FDG uptake and PDL-1 expression. PDL-1 (programmed death protein ligand-1) is a protein that cancer cells use to evade the immune system, and its presence makes tumors more likely to respond to immunotherapy drugs like pembrolizumab (Keytruda).

This is particularly relevant given the results of the KEYNOTE-522 trial, which demonstrated improved overall survival in TNBC patients with PD-L1-positive tumors treated with pembrolizumab. The ability of PET to suggest PDL-1 status raises the possibility of using imaging as a screening tool to identify which patients might benefit from immunotherapy—potentially guiding treatment before or without the need for a fresh biopsy.

Tumor Immune Microenvironment

Kimura and colleagues (2023) investigated whether the metabolic parameter SUVmax (standardized uptake value, a measure of how much tracer is taken up by the tumor) could provide information about the tumor immune microenvironment (TIME)—the complex ecosystem of immune cells surrounding and infiltrating the tumor. They studied 54 patients and found that SUVmax significantly correlated with the CD8/FOXP3 ratio, an immune-functional marker of tumor-infiltrating lymphocytes (TILs). TILs are major components of the tumor immune microenvironment and are substantially related to tumor progression and response to chemotherapy.

A high CD8/FOXP3 ratio corresponds to a high SUVmax, meaning the more metabolically active tumors tend to have a more favorable immune profile. Intriguingly, the CD8/FOXP3 ratio was the only independent predictive factor for pathological complete response at multivariate analysis in that study. This suggests that [18F]FDG PET/CT might help predict the effects of neoadjuvant chemotherapy in TNBC by reflecting the underlying immune state of the tumor.

Tumor Heterogeneity and Immunotherapy Outcome

Xie et al. (2022) studied 32 patients and reported a correlation between [18F]FDG uptake and tumor heterogeneity—the degree to which cancer cells within a single tumor differ from each other. Their finding showed that baseline intratumoral heterogeneity (a measure of how uneven the [18F]FDG signal is within the tumor) predicts immunotherapy response. This is a promising avenue for identifying, before treatment begins, which patients are most likely to benefit from immunotherapy.

Monitoring Response to Chemotherapy

Perhaps the most extensively studied role of PET imaging in TNBC is in the neoadjuvant chemotherapy (NAC) setting—that is, chemotherapy given before surgery to shrink tumors and eliminate microscopic spread. The review found that 10 of the 28 selected studies focused on this application, making it the most investigated area overall.

The key concept in this setting is pathological complete response (pCR), which means that when the surgeon removes the tumor after chemotherapy, no cancer cells are found in the tissue. Achieving pCR is strongly associated with better long-term outcomes, including longer disease-free survival and overall survival. Being able to predict early—ideally during chemotherapy—whether a patient is on track to achieve pCR would allow doctors to adjust treatment plans in real time.

The standard approach is to measure the maximum standardized uptake value (SUVmax) at baseline and again after one or more cycles of chemotherapy. A drop in SUVmax indicates that the tumor is becoming less metabolically active, which suggests it is responding to treatment.

Key Findings from NAC Studies

• Groheux et al. (2012) — 20 patients (prospective): ΔSUVmax (the change in SUVmax) after 2 cycles of NAC correlated with better prognosis and pCR
• Humbert et al. (2015) — 50 patients (prospective): ΔSUVmax after just 1 cycle of NAC was a reliable predictor of pCR
• Kiyoto et al. (2015) — 32 patients: ΔSUVmax after completing NAC predicted pCR and disease-free survival
• Groheux et al. (2016) — 78 patients (prospective): ΔSUVmax after 2 cycles predicted pCR and event-free survival, but importantly, a different optimal cut-off value was needed for each distinct chemotherapy regimen
• Groheux et al. (2018) — 55 patients: Baseline SUVmax combined with a genomic grade index (GGI) as well as ΔSUVmax after NAC predicted pCR; both ΔSUVmax after NAC and pCR were predictors of event-free survival
• Basnet et al. (2020) — 30 patients: A 50% reduction in SUVmax after 3 cycles of NAC could be applied to discriminate responders from non-responders
• Seban et al. (2023) — 191 patients: Tumor SUVmax and total metabolic tumor volume (MTV) were predictors of pCR at both univariate and multivariate analysis in both NAC and NACI (neoadjuvant chemotherapy plus immunotherapy) cohorts
• Bouron et al. (2021) — 74 patients: Notably, this study found that conventional and textural parameters from baseline [18F]FDG PET failed to predict pCR after NAC—a reminder that not all PET parameters are equally useful

Combining PET with Pathology

Groheux and colleagues (2015) studied 85 patients and showed that combining the results of baseline [18F]FDG PET with pathology findings after NAC allows doctors to stratify TNBC patients into three subgroups with different prognoses. This integrated approach—imaging plus pathology—provides more nuanced prognostic information than either method alone.

Looking Beyond Metabolism: Tumor Blood Flow

Humbert et al. (2016) took a different approach with 46 patients, investigating whether changes in tumor blood flow (ΔBF) at dynamic [18F]FDG PET could provide additional prognostic information. A decrease in blood flow between baseline and after 1 cycle of NAC—which serves as a surrogate marker of tumor perfusion and neoangiogenesis (the growth of new blood vessels that feed the tumor)—was found to be an incremental prognostic stratifier when combined with pCR. In other words, combining metabolic response (pCR) with functional response (blood flow changes) gives a more complete picture of how well the tumor is responding.

For patients undergoing chemotherapy, these findings suggest that serial PET scans can provide a real-time window into how effectively the tumor is being killed. Rather than waiting until after surgery to learn whether chemotherapy worked, patients and their care teams can gauge progress after just one or two cycles and make adjustments if needed.

PET and Long-Term Prognosis

Beyond predicting treatment response, PET imaging parameters can also provide crucial information about long-term prognosis in patients with metastatic TNBC. The review identified several studies examining this question.

Marinelli et al. (2016) studied 47 patients with metastatic TNBC and found that metabolic tumor volume (MTV)—a measure of the total volume of metabolically active tumor tissue—was a strong prognostic factor. Patients with higher MTV had worse outcomes, presumably because they had a larger total burden of active disease.

Kim et al. (2017) evaluated 228 patients and found that lymph node PET parameters are independent prognostic factors in TNBC. This means that even after accounting for other known risk factors, the metabolic activity seen in lymph nodes on PET scans provides additional information about how the disease is likely to progress.

Two additional studies focused on tumor heterogeneity in the metastatic setting:

• Xie et al. (2019) — 31 patients: Intratumor heterogeneity assessed by a lung index (LI) and total lesion glycolysis (TLG, a measure combining both metabolic activity and volume) of metastatic TNBC on baseline PET/CT scans had predictive value for treatment outcome and overall survival in patients receiving first-line platinum-based therapy
• Gong et al. (2018) — 42 patients: Heterogeneity index (HI) and MAX among metastatic lesions—especially in visceral lesions (those involving internal organs like the liver or lungs)—on baseline PET/CT had predictive value for treatment response to first-line platinum-based therapy

These findings matter for patients because they suggest that PET scans can do more than just show where cancer is located. The specific patterns of metabolic activity—how much, how intense, and how heterogeneous—can provide a wealth of prognostic information that helps doctors counsel patients about what to expect and potentially select more aggressive or targeted treatments for those at highest risk.

New Frontiers: PSMA Tracers and Radiomics

The review also highlighted two emerging areas of research that could significantly expand the role of PET imaging in TNBC: PSMA-targeted tracers and radiomics.

PSMA-Targeted PET Imaging

Prostate-specific membrane antigen (PSMA) is a protein that is overexpressed by the new blood vessels (neovasculature) that feed TNBC tumors. Two studies in this review explored the use of PSMA-ligand PET agents—[68Ga]Ga-PSMA-11 and [18F]PSMA-1007—which are tracers that bind to PSMA:

• Andryszak et al. (2024) — 10 patients (prospective): The study found comparable uptake of both tracers (PSMA and [18F]FDG) in primary tumors and metastases, but PSMA was superior in brain lesions. This is significant because brain metastases are particularly difficult to detect and treat in TNBC patients.
• Arslan et al. (2023) — 42 patients (prospective): The study compared PSMA and [18F]FDG, finding that [18F]FDG showed higher uptake values than PSMA, but a precise assessment of PSMA's diagnostic performance was not provided. The authors noted that PSMA might be useful for theranostic applications—a combined diagnostic-and-treatment platform.

The concept of theranostics (combining diagnosis and therapy into a single platform) is a particularly exciting frontier. If PSMA-targeted tracers can both image TNBC tumors and deliver therapeutic radiation to them—an approach already successfully used in prostate cancer—it could open entirely new treatment avenues for TNBC patients, particularly those with metastatic disease who have exhausted conventional options.

Radiomics: Extracting More Data from Images

Radiomics is an emerging discipline that involves extracting quantitative and reproducible data from medical images. These data, called "features," go far beyond what the human eye can see—thousands of mathematical measurements of texture, shape, intensity, and spatial relationships between pixels.

Two studies in this review explored radiomics in TNBC:

• Romeo et al. (2022) — 86 patients (prospective): This study used [18F]FDG PET/MRI radiomic data to train a machine learning model that showed high accuracy in discriminating TNBC from other breast cancer subtypes. This could potentially help in diagnosis and treatment planning, especially in cases where biopsy is difficult or when additional confirmation is needed.
• Bouron et al. (2022) — 111 patients: Textural features from baseline [18F]FDG PET/CT—combined with metabolic and volumetric parameters—had prognostic value for identifying high-relapse-risk groups in early TNBC patients. This means radiomics could help identify which patients with early-stage disease are at greatest risk of recurrence and might benefit from more aggressive treatment.

For patients, radiomics holds the promise of extracting far more information from PET scans than is currently used in clinical practice. A single scan could potentially provide hundreds of data points that help predict treatment response, risk of recurrence, and optimal treatment selection—all without additional procedures or radiation exposure.

PET vs. MRI

One study in the review directly compared [18F]FDG PET/CT with MRI. Choi and colleagues (2018) studied 60 patients and found that heterogeneous or rim enhancement (a pattern where the edges of the tumor light up but the center doesn't), high signal on T2-weighted images, and peritumoral edema (swelling around the tumor seen on MRI) were all correlated with SUVmax on PET. This suggests that the two imaging modalities provide complementary information, with MRI giving structural detail and PET providing metabolic activity data.

What This Means for Patients

Pulling together the evidence from all 28 studies and 2,870 patients, this systematic review provides a clear picture of the importance of PET imaging in TNBC management. The findings have several direct implications for patients.

First, if you have been newly diagnosed with TNBC, [18F]FDG PET/CT can play an essential role in initial staging. The Ulaner study's finding that 15% of stage IIB patients had hidden distant metastases detected only by PET is particularly striking. This means that for a substantial minority of patients, PET changes the stage of their disease and, consequently, the entire treatment approach. Patients whose cancer is found to have spread are typically switched from local therapies (surgery, radiation) to systemic treatments (chemotherapy, immunotherapy) that address cancer throughout the body.

Second, PET can function as a non-invasive "biopsy" of tumor biology. Because [18F]FDG uptake correlates with Ki67, AR expression, PDL-1 status, and immune cell infiltration, your PET scan may provide clues about your tumor's molecular profile without the need for repeated tissue sampling. This is particularly valuable when biopsies are technically difficult, when tumors have changed over time, or when doctors need information quickly to make treatment decisions. A high-uptake tumor might suggest a more aggressive, fast-growing cancer or one that expresses PDL-1 and therefore might respond to immunotherapy.

Third, serial PET scans during chemotherapy provide a real-time window into treatment effectiveness. The ability to detect a meaningful drop in SUVmax after just one or two cycles of chemotherapy—as demonstrated by Humbert and colleagues—means that patients who are not responding can potentially be identified early, allowing their treatment plan to be modified weeks or months earlier than waiting for surgical pathology results. Conversely, a rapid metabolic response provides encouraging early evidence that the treatment is working.

Fourth, PET parameters can inform prognosis. Metrics like metabolic tumor volume (MTV), total lesion glycolysis (TLG), heterogeneity indices, and lung index provide prognostic information in metastatic TNBC, helping doctors and patients understand the likely course of the disease and tailor treatment intensity accordingly.

Fifth, new PET tracers may expand treatment options. PSMA-targeted tracers show particular promise for detecting brain metastases—a clinically challenging complication of TNBC—and could eventually enable theranostic approaches where the same molecule that images the tumor also delivers targeted radiation therapy to it. Radiomics represents another frontier where more sophisticated analysis of standard scans could yield even more predictive information.

Study Limitations

It's important for patients and caregivers to understand the limitations of this review and the research it analyzed:

• Heterogeneity of studies: The 28 studies varied considerably in their clinical settings (staging vs. treatment response vs. prognosis), patient populations, treatment regimens, and PET parameters analyzed. This heterogeneity prevented a meta-analysis from being performed and makes it difficult to establish universal, standardized cut-off values for key parameters like SUVmax.
• Variable study quality: Only 30% of the studies were rated as having appropriate methodology, and the study design was unclear in one-third of the papers. Sixteen studies (59%) were rated as high value, but 11% were rated low value.
• Retrospective design predominance: Most studies (71.4%) were retrospective, which limits their ability to establish cause-and-effect relationships. Retrospective studies can be affected by selection bias and other methodological concerns.
• Different cut-off values: The studies used various SUVmax cut-off values to predict pCR, and importantly, as Groheux et al. (2016) demonstrated, different optimal cut-offs are needed for different chemotherapy regimens. This makes it difficult to apply a universal threshold in clinical practice.
• Uneven representation of applications: Some clinical applications of PET were studied more extensively than others. For example, while 10 studies examined the NAC setting, only 2 studies each examined PSMA-PET and radiomics.
• Small sample sizes in some studies: Several studies had relatively small patient populations (as few as 10 patients in the Andryszak study and 20 in the Groheux 2012 study), which limits the statistical power and generalizability of their findings.
• [18F]FDG dominance: The vast majority of studies used [18F]FDG-based PET, with only two studies using PSMA-ligand agents. Evidence for the newer tracers is thus preliminary.
• Lack of standardized radiomic protocols: Radiomic approaches, while promising, suffer from a lack of standardization in how features are extracted and analyzed, which affects the reproducibility of results across different centers.
• The studies were not blinded trials: The PET scans were interpreted in the context of known clinical information, which can introduce interpretation bias.

Recommendations for Patients

If you or a loved one is facing a TNBC diagnosis or treatment, here are some practical recommendations based on the findings of this review:

1. Ask about PET imaging for initial staging. Given the evidence that PET can detect hidden metastases in a significant percentage of patients (15% in the largest study), discuss with your oncology team whether a baseline [18F]FDG PET/CT is appropriate before starting treatment. This is especially relevant if you have stage IIB disease or higher, though the optimal timing and use should be individualized.
2. Inquire about serial PET scans during neoadjuvant chemotherapy. If you are receiving chemotherapy before surgery, ask whether your treatment center offers early PET response assessment. Research shows that changes in SUVmax after just 1–2 cycles of chemotherapy can predict whether you will achieve a pathological complete response. Early identification of non-response could allow for treatment modification.
3. Understand your PET results in context. PET results are not "positive" or "negative" in isolation—they need to be interpreted in light of your specific tumor biology (biomarker status), treatment regimen, and clinical situation. A high SUVmax might indicate an aggressive tumor but also one that might express PDL-1 and respond to immunotherapy. Ask your care team to explain what your specific PET parameters mean in your unique context.
4. Ask about clinical trials involving new PET tracers. PSMA-targeted PET imaging and radiomic analysis are active areas of research that could offer additional information beyond standard [18F]FDG PET. If you have metastatic TNBC—particularly if brain metastases are a concern—ask whether PSMA-PET is available at your center or through clinical trials.
5. Be aware of the limitations. While PET imaging provides valuable information, it is not infallible. Some studies showed that baseline PET parameters failed to predict pCR, and cut-off values vary by chemotherapy regimen. PET results should be used as one piece of the puzzle alongside biopsy results, pathology findings, and clinical judgment—not as a sole determinant of your treatment plan.
6. When possible, seek care at specialized centers. The reliability of PET imaging and its interpretation depends on expertise. Centers with dedicated breast cancer imaging and multidisciplinary teams are more likely to use PET imaging optimally and to integrate the results appropriately with other diagnostic information.
7. Ask about combining imaging with genetic testing. Some studies combined PET parameters with genomic information (such as the genomic grade index) for more accurate prediction. If you have had genomic testing of your tumor, ask whether your care team integrates this information with imaging findings.
8. Educate yourself about emerging theranostic approaches. While not yet clinically available for TNBC, the concept of PSMA-based theranostics (combining imaging with targeted therapy) is rapidly evolving. Staying informed about these developments can help you have informed conversations with your oncology team about future treatment options.

The bottom line: [18F]FDG PET/CT is an essential tool in the modern management of triple-negative breast cancer. It provides critical information for staging, helps predict and monitor response to chemotherapy, correlates with important molecular biomarkers that guide treatment selection, and offers valuable prognostic information. As PSMA-targeted tracers and radiomic analysis continue to be refined through prospective studies, the role of PET imaging in TNBC is likely to expand even further, bringing the promise of increasingly personalized, image-guided cancer care closer to reality.

Frequently Asked Questions

What is triple-negative breast cancer and why is it hard to treat?

Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 receptors, so hormonal therapy and HER2-targeted drugs do not work. It accounts for 15–20% of breast cancers, mainly affects people under 40, and has a higher recurrence rate and poorer prognosis than other subtypes.

How does PET imaging work for triple-negative breast cancer?

PET shows how actively cells use energy. Cancer cells are highly metabolically active and take up [18F]FDG, a radioactive glucose. TNBC and HER2-enriched tumors typically show high FDG uptake, while luminal A cancers show faint uptake, making PET particularly useful for TNBC.

Can PET scans predict whether chemotherapy will work?

Yes. In a prospective study of 50 patients, a drop in SUVmax after just one cycle of neoadjuvant chemotherapy reliably predicted whether patients would achieve a pathological complete response. Other studies found similar results after two or three cycles, though optimal cut-offs vary by chemotherapy regimen.

Can PET imaging tell if I might benefit from immunotherapy?

In a study of 145 TNBC patients, high [18F]FDG uptake correlated with PDL-1 expression, a marker that can predict response to immunotherapy. Another study of 54 patients found that a metabolic parameter correlated with an immune marker that predicted pathological complete response. This suggests PET might help identify candidates, but more research is needed.

What are PSMA tracers and radiomics for TNBC?

PSMA-targeted tracers bind to a protein on new blood vessels feeding TNBC tumors. In a study of 10 patients, PSMA was superior to FDG for detecting brain metastases. Radiomics extracts hundreds of quantitative features from images; in one study, PET/MRI radiomic data discriminated TNBC from other subtypes with high accuracy.

What are the limitations of PET imaging for triple-negative breast cancer?

The 28 studies varied in design, quality, and PET parameters, preventing a meta-analysis. Most were retrospective, 30% had appropriate methodology, and optimal SUVmax cut-offs differed by chemotherapy regimen. Small sample sizes in some studies and lack of standardized radiomic protocols also limit conclusions.

Can a second opinion on PET imaging change my treatment plan for triple-negative breast cancer?

A PET scan can change TNBC management in several ways. In one study, PET/CT upstaged 15% of early-stage patients by finding hidden metastases, redirecting them from surgery to systemic therapy. PET uptake also correlates with biomarkers like PDL-1, Ki67, and androgen receptor, which may influence immunotherapy or anti-androgen choices. During neoadjuvant chemotherapy, a drop in SUVmax after one or two cycles can predict pathological complete response, so an early review of serial scans might suggest adjusting treatment. Because these decisions rely on expert image interpretation, a second opinion on your imaging and pathology could meaningfully change your treatment plan. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original Article: "The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective"

Authors: Luca Filippi, Luca Urso, Cristina Ferrari, Priscilla Guglielmo, Laura Evangelista

Journal: European Journal of Nuclear Medicine and Molecular Imaging

Publication Date: Received 31 May 2024; Accepted 21 July 2024

DOI: https://doi.org/10.1007/s00259-024-06866-9

Affiliation note: Luca Urso, Cristina Ferrari, and Priscilla Guglielmo contributed equally as second authors.

This patient-friendly article is based on a peer-reviewed systematic review published in the European Journal of Nuclear Medicine and Molecular Imaging. The original review was registered with the authors' institutional affiliations at Fondazione PTV Policlinico Tor Vergata University Hospital (Rome, Italy), University of Ferrara (Ferrara, Italy), University of Bari "Aldo Moro" (Bari, Italy), Humanitas Gavazzeni (Bergamo, Italy), IRCCS Humanitas Research Hospital (Rozzano, Italy), and Humanitas University (Pieve Emanuele, Italy).

The information in this article is intended for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of your physician or other qualified health provider with any questions you may have regarding your medical condition.